Scarica l'app Stockscreener
2.80
7.59%
-0.23
Dopo l'orario di chiusura:
2.85
0.05
+1.79%
Precedente Chiudi:
$3.03
Aprire:
$3.06
Volume 24 ore:
531.41K
Relative Volume:
1.56
Capitalizzazione di mercato:
$130.02M
Reddito:
-
Utile/perdita netta:
$-42.05M
Rapporto P/E:
-0.9929
EPS:
-2.82
Flusso di cassa netto:
$-35.26M
1 W Prestazione:
-8.50%
1M Prestazione:
-7.89%
6M Prestazione:
-46.97%
1 anno Prestazione:
+33.97%
Intervallo 1D:
$2.79
$3.095
Intervallo di 1 settimana:
$2.79
$3.095
Portata 52W:
$1.595
$10.48
Protara Therapeutics Inc Stock (TARA) Company Profile
Nome
Protara Therapeutics Inc
Settore
Industria
Telefono
646-844-0337
Indirizzo
345 PARK AVENUE SOUTH, NEW YORK, NY
Confronta TARA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
2.80 | 130.02M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-16 | Iniziato | Scotiabank | Sector Outperform |
| 2025-03-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-10 | Ripresa | Guggenheim | Buy |
| 2021-06-04 | Iniziato | H.C. Wainwright | Buy |
| 2021-02-17 | Iniziato | Oppenheimer | Outperform |
| 2020-10-19 | Iniziato | Cowen | Outperform |
| 2020-07-29 | Iniziato | Guggenheim | Buy |
Mostra tutto
Protara Therapeutics Inc Borsa (TARA) Ultime notizie
Non-Muscle Invasive Bladder Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics - The Globe and Mail
Why EchoStar Stock Is Soaring Higher Today - The Globe and Mail
Two Sigma Investments LP Cuts Stock Holdings in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Therapeutics: Marching On To A Hopefully Eventful Back Half Of 2025 (NASDAQ:TARA) - Seeking Alpha
SoundHound AI (SOUN): This High-Potential Growth Stock Could Be Your Smartest Bet under $10 - The Globe and Mail
Where Will Uber Stock Be in 5 Years? - The Globe and Mail
Company News for Jun 13, 2025 - The Globe and Mail
Protara Therapeutics Holds Annual Stockholders Meeting - TipRanks
These 3 ‘Bro Billionaire’ Stocks Are Wildly Outperforming in Trump’s Market - The Globe and Mail
Kantar appoints Jeff Greenspoon as CEO, Americas - The Globe and Mail
Cantor Fitzgerald Forecasts TARA FY2026 Earnings - Defense World
Squarepoint Ops LLC Makes New $110,000 Investment in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Steven Hudson buying at ECN Capital (ECN) - The Globe and Mail
Protara Therapeutics, Inc. (NASDAQ:TARA) Position Increased by Bank of America Corp DE - Defense World
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of “Buy” by Analysts - Defense World
Why Shares of Tesla Are Sinking Today - The Globe and Mail
Is Costco a Buy Now? - The Globe and Mail
Millennium Management LLC Purchases 357,051 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Therapeutics names new Chief Commercial Officer By Investing.com - Investing.com South Africa
Protara Therapeutics (TARA) Appoints New Chief Commercial Officer | TARA Stock News - GuruFocus
Protara Therapeutics names new Chief Commercial Officer - Investing.com
Protara Therapeutics Names William Conkling as Chief Commercial Officer - MarketScreener
Protara Therapeutics Announces Appointment Of William Conkling As Chief Commercial Officer - marketscreener.com
Protara Therapeutics Announces Appointment of William Conkling a - GuruFocus
Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer - GlobeNewswire
Cancer Drug Veteran Behind Trodelvy Launch Joins Protara as Commercial Chief to Lead Market Strategy - Stock Titan
The Next Stock I'm Buying? - The Globe and Mail
Transcript : Protara Therapeutics, Inc. Presents at TD Cowen's 6th Annual Oncology Innovation Summit, May-27-2025 01 - marketscreener.com
Jones Trading Initiates Coverage of Protara Therapeutics (TARA) with Buy Recommendation - Nasdaq
Protara Therapeutics (TARA) Initiates Coverage with a Buy Rating - GuruFocus
Protara Therapeutics (TARA) Initiates Coverage with a Buy Rating | TARA Stock News - GuruFocus
Protara Therapeutics (TARA) Receives Buy Rating with $21 Price T - GuruFocus
Jones Initiates Protara Therapeutics at Buy With $21 Price Target - marketscreener.com
Richard Levy Spends US$64k On Protara Therapeutics Stock - Yahoo Finance
BNP Paribas Financial Markets Purchases Shares of 151,906 Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Dimensional Fund Advisors LP Makes New $111,000 Investment in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Richard Levy Bought 65% More Shares In Protara Therapeutics - simplywall.st
Insider Buying: Richard Levy Acquires 20,000 Shares of Protara T - GuruFocus
With 73% ownership, Protara Therapeutics, Inc. (NASDAQ:TARA) boasts of strong institutional backing - Yahoo Finance
Protara Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of “Buy” from Brokerages - Defense World
Protara Therapeutics Reports Q1 2025 Financial Results - TipRanks
Protara Therapeutics: Q1 Earnings Snapshot - New Haven Register
Barclays PLC Takes $492,000 Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Protara Therapeutics’ TARA-002: A Promising Alternative for NMIBC with Strong Efficacy and Safety Profile - TipRanks
Protara (TARA) Strengthens Leadership with Key Appointments | TA - GuruFocus
Protara Therapeutics (TARA) Sees Positive Results in TARA-002 Trial | TARA Stock News - GuruFocus
Protara (TARA) Strengthens Leadership with Key Appointments | TARA Stock News - GuruFocus
Protara Therapeutics Inc Azioni (TARA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Protara Therapeutics Inc Azioni (TARA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Zummo Jacqueline | Chf Scientific Operations Off |
Mar 26 '25 |
Sale |
4.53 |
21,224 |
96,145 |
98,861 |
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):